CYTH2

Across TCGA pan-cancer cohorts, CYTH2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYTH2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CYTH2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYTH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, KIRP, and LUAD are the cancer types where CYTH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.287	0.903	.001	24	view →
KIRP	OS	Median	All	0.199	0.903	<.001	15	view →
LUAD	OS	Median	All	0.338	0.834	.004	6	view →
SKCM	OS	Median	III,IV	0.290	0.707	.009	6	view →
UCEC	DFS	Median	All	0.957	0.627	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYTH2–BRCA (DFS)

Open the BRCA breakdown →